Arcus Biosciences Inc (RCUS) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Arcus Biosciences Inc $3.92, price $24.44, upside -84.0%, quality 32 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Arcus Biosciences Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $6.87 – $48.47 · fair‑value band $2.59 – $4.90 · the $24.44 price screens above the $3.92 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Arcus Biosciences in your weekly email
Every Wednesday you see whether Arcus Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
Show more
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Stock analysis
Arcus Biosciences Inc (RCUS) currently trades at $24.44, while our model-based Fair Value estimate is $3.92, 84.0% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: $2.59 (bear) to $4.90 (bull), the price of $24.44 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Arcus Biosciences Inc reported revenue of $247M in FY2025 versus $383M in FY2021, a compound −10.4%/yr. Reported net income was −$353M in FY2025.
Key figures
Market cap $4.0B · P/S ratio 34.4 · EPS (TTM) $−4.13 · Net margin −143% · Return on equity −90.8% · Return on assets (EBIT) −22.2% · Operating margin −234% · Revenue (TTM) $117M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).
What moves the price
The share trades about 23% below its 52-week high and 83% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −84%, RCUS screens richer than that median.
Fair Value models
Bear $2.59Fair Value $3.92Bull $4.90
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.29/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−4.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.9%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+90.7%
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−159.0% (2020) → −156.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (90 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Very negative
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 629 stocks
Beats the industry median on 0/8 measures
Overall it trails its industry peers.
Valuation
Quality Score35 · Below median
Fair Value upside−84.5% · Bottom 25%
Profitability
Return on assets−30.4% · Bottom 25%
Net margin (TTM)−142.9% · Bottom 25%
Growth and dividend
Revenue growth−74.4% · Bottom 25%
Balance sheet
Debt / equity0.16× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B6.37× · Priciest 25%
P/S (TTM)34.36× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)92· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Arcus Biosciences Inc (RCUS) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $3.92 versus a price of $24.44, about −84% upside (overvalued).
What is the fair value of RCUS?
Our model-based fair value for Arcus Biosciences Inc is $3.92 (as of Sep 24, 2026), built from audited fundamentals. The current price: $24.44.
What is the quality score of RCUS?
Arcus Biosciences Inc has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Arcus Biosciences Inc (RCUS)?
Our model-based price target is the fair value of $3.92 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $2.59, optimistic scenario $4.90. It is a calculation from audited fundamentals, not an analyst target.
What is the Arcus Biosciences Inc stock forecast for 2026?
Our models put fair value at $3.92, about −84% upside versus a price of $24.44 (overvalued). Cautious scenario $2.59, optimistic scenario $4.90. The calculation is refreshed regularly with new filings.
What is the revenue of Arcus Biosciences Inc (RCUS)?
Arcus Biosciences Inc reported trailing-twelve-month revenue of about $117M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Arcus Biosciences Inc (RCUS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Arcus Biosciences Inc it is $3.92 per share (as of Sep 24, 2026), against a price of $24.44. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Arcus Biosciences Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, RCUS trades above its calculated fair value: price $24.44, fair value $3.92, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RCUS?
No. The price is what the market pays today ($24.44); the fair value is what the company's own numbers justify ($3.92). For Arcus Biosciences Inc the two are $20.52 per share apart. That gap is exactly why we show both numbers side by side.
How much is Arcus Biosciences Inc worth?
The market values Arcus Biosciences Inc at about $4.0B (market capitalisation, as of Sep 24, 2026). Per share that is $24.44; our models calculate a fair value of $3.92 per share.
What do the bullish and bearish scenarios say about RCUS?
Our models span a range for Arcus Biosciences Inc: cautious scenario $2.59, base $3.92, optimistic $4.90 per share (as of Sep 24, 2026, price $24.44). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Arcus Biosciences Inc (RCUS)?
Balance-sheet figures for Arcus Biosciences Inc (as of Sep 24, 2026): return on equity −90.8%, debt of 0.16 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is RCUS from its 52-week high?
Arcus Biosciences Inc trades at $24.44, about 23% below its 52-week high of $31.57 and 83% above the low of $13.35 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $3.92 is for.
Which stocks are comparable to Arcus Biosciences Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Arcus Biosciences Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $24.44, calculated fair value $3.92 (−84%), Quality Score 32/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RCUS calculated?
We run Arcus Biosciences Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.92, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Arcus Biosciences Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Arcus Biosciences Inc (RCUS)?
The closing price on Oct 2, 2026 was $24.44. Our model-based fair value is $3.92, about −84% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Arcus Biosciences Inc right now?
The price sits above even our optimistic bull case ($4.90). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($2.59 to $4.90) leaves room in how you read the outcome.
Key figures of Arcus Biosciences Inc
How large is the market capitalisation of Arcus Biosciences Inc (RCUS)?
The market capitalisation of Arcus Biosciences Inc is $4.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Arcus Biosciences Inc (RCUS)?
The price-to-sales ratio of Arcus Biosciences Inc is 34.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Arcus Biosciences Inc (RCUS)?
Earnings per share at Arcus Biosciences Inc are $−4.13. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Arcus Biosciences Inc (RCUS)?
The net margin of Arcus Biosciences Inc is −143% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Arcus Biosciences Inc (RCUS)?
The return on equity (ROE) of Arcus Biosciences Inc is −90.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Arcus Biosciences Inc (RCUS)?
On an EBIT basis the return on assets of Arcus Biosciences Inc is −22.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Arcus Biosciences Inc (RCUS)?
The operating margin of Arcus Biosciences Inc is −234% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Arcus Biosciences Inc (RCUS)?
Revenue at Arcus Biosciences Inc is growing −74.4% versus a year earlier (3y avg +30.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Arcus Biosciences Inc (RCUS) generate?
The free cash flow of Arcus Biosciences Inc is −$484M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Arcus Biosciences Inc (RCUS) hold?
Arcus Biosciences Inc holds more cash than debt, $123M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Arcus Biosciences Inc in the live analysis
One click puts Arcus Biosciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026